Investor Presentaiton
53
53
MEDI0457 (HPV16/18) Induces Robust Anti-Tumor Immunity
in Head and Neck Cancer Phase 1 study of MEDI0457 (INO-3112) in 22 HPV+ HNSCC Patients
Pre-MEDI0457
Post-MEDI0457
Strong invasion by CD8 T cells into tumors following immunization with
MEDI0457 in HPV associated HNSCCa.
CD8+ T cell expression
Perforin expression
Reciprocal Anti HPV18
E7 Endpoint Titer
SFU/10° PBMCS
Induction of T cells:
Quantitative non-cultured ELISpots
4001
350-
300-
250
200-
150
100
50-
0
Baseline
Peak Response
Induction of Antibodies:
Endpoint titers to HPV18 E7
2x103
1x103-
5x102
Aggarwal et al Clinical Cancer Research 2018
1x100 -8888888e-
Baseline
Most participants respond immunologically to the vaccine
AstraZeneca
Perelman
School of Medicine
UNIVERSITY of PENNSYLVANIA
THE
XXX WISTAR
INSTITUTE
eeee
Peak Response
INOVIO
POWERING DNA MEDICINESView entire presentation